Cargando…

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection

BACKGROUND: The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Young Saing, Jeong, Chi-Young, Song, Haa-Na, Kim, Tae Hyo, Kim, Hong Jun, Lee, Young-Joon, Hong, Soon Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237216/ https://www.ncbi.nlm.nih.gov/pubmed/28086990 http://dx.doi.org/10.1186/s40880-017-0182-y

Ejemplares similares

Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
por: Kim, Hyera, et al.
Publicado: (2020)

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
por: Ji, Jun Ho, et al.
Publicado: (2018)

Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
por: Go, Se-Il, et al.
Publicado: (2016)

Correction to: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
por: Kim, Hyera, et al.
Publicado: (2020)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
por: Lim, Kyu-Hyoung, et al.
Publicado: (2009)

Adjuvant Radio-chemotherapy for extrahepatic biliary tract cancers
por: Bonet Beltrán, Marta, et al.
Publicado: (2011)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2019)

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
por: Kim, Seong-Geun, et al.
Publicado: (2016)

Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB–IIA cervical cancer patients
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis
por: Miyata, Yoichi, et al.
Publicado: (2021)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study
por: Tae, Jong Hyun, et al.
Publicado: (2022)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
por: Min, Byung-Hoon, et al.
Publicado: (2011)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
por: Kim, Ryul, et al.
Publicado: (2022)

Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
por: Park, Se Jun, et al.
Publicado: (2023)

Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database
por: Zhu, Yueting, et al.
Publicado: (2023)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Adjuvant therapy of biliary tract cancers
por: Kefas, Joanna, et al.
Publicado: (2023)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma
por: Li, Yunfeng, et al.
Publicado: (2023)

Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy
por: Seo, Seyoung, et al.
Publicado: (2019)

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
por: Seo, Seyoung, et al.
Publicado: (2016)

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
por: Jung, Hyun Ae, et al.
Publicado: (2013)

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
por: Park, Seong Yong, et al.
Publicado: (2023)

Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer
por: Jeon, Chul-Hyo, et al.
Publicado: (2019)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
por: Park, Seong Yong, et al.
Publicado: (2013)

Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment
por: You, Min Su, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mc4pfd13a3f0j4q60hsgu3ffcm